bêta
IA Trial Radar
L'essai clinique NCT07254364 pour Insulin Response est en recrutement. Consultez la vue en carte du Radar des Essais Cliniques et les outils de découverte par IA pour tous les détails, ou posez vos questions ici.
Un essai clinique correspond aux filtres sélectionnés
Vue en carte

Advancing Precision Nutrition: Wearable Technology for Noninvasive Insulin Monitoring

En recrutement
Les détails de l'essai clinique sont principalement disponibles en anglais. Cependant, l'IA Trial Radar peut vous aider ! Cliquez simplement sur 'Expliquer l'essai' pour voir et discuter des informations sur l'essai dans la langue sélectionnée.
L'étude clinique NCT07254364 est un essai interventionnel pour Insulin Response. Son statut actuel est : en recrutement. L'étude a débuté le 11 septembre 2025 et vise à recruter 32 participants. Dirigé par Texas A&M University, l'essai devrait être terminé d'ici le 1 décembre 2026. Les données du site ClinicalTrials.gov ont été mises à jour pour la dernière fois le 28 novembre 2025.
Résumé succinct
Noninvasively monitoring insulin is crucial for advancing precision nutrition and promoting healthy living by enabling a deeper understanding of individual metabolic responses to dietary intake. Insulin is a key regulator of blood sugar and energy metabolism, and its dysregulation is linked to conditions such as diabetes, obesity, and metabolic syndrome. By noninvasively tracking insulin levels, individuals can gain real-time insights into how their body processes different foods, allowing for the personalization of diets to optimize metabolic health, manage weight, and reduce disease risk. This approach also empowers proactive lifestyle adjustments to maintain insulin sensitivity, improve glycemic control, and enhance overall well-being. Decentralized insulin quantification in biofluids, including saliva and serum, based on lateral flow assay or electrochemical sensor has been reported. However, these approaches have poor sensitivity and fail to quantify insulin with a high temporal resolution.
Description détaillée
The goal of the proposed research is to develop a wearable device that can directly stimulate sweat secretion and rapidly quantify the concentration of insulin in sweat. In stark contrast to a blood draw and subsequent insulin quantification in a clinical lab, the envisioned wearable sweat sensor can noninvasively and rapidly quantify insulin at any desired time at home. This study will validate the performance of the wearable devices for in situ quantification of insulin in sweat and determine the concentration correlation between sweat, dermal interstitial fluid, and blood.

The study will take place at the research facility of the Center for Translational Research on Aging and Longevity (CTRAL), Texas A&M University located in the Human Clinical Research Building) affiliated with Texas A&M University. Some study procedures (e.g., body composition) may be skipped if completed within the past 3 months at CTRAL. All data will be recorded in Case Report Form and stored in the Research Electronic Data Capturing (REDCap) System.

Subjects will be asked to arrive in the fasted state on all study days. Fasting prior to screening is not required. On the screening day, body weight, height, and body composition by Dualenergy X-ray absorptiometry (DXA) will be measured. In addition, The SixMinute Walk Test (6MWT) and skeletal muscle function tests will be assessed at the end of each screening visit. Questionnaires about your overall health and well-being will also be completed. The study visit will begin with vital signs. Before administration of the feeding or the tracer solution, baseline blood will be collected for measurement of the natural enrichment of metabolites. The research nurse will place a catheter (small, flexible, plastic tube) in a vein of the arm or hand. The hand will be placed in a warmed box to increase blood flow. There will be a device with electrodes used to generate and collect sweat on your forearm. Once sweat collection is started, we will also apply a microneedle patch to the forearm of the subject for 5-30 minutes duration. Microneedle patches (sensors) are small flexible sticker-like devices. They will be applied to the skin using a small spring loaded applicator to measure the chemical analytes in the dermal interstitial fluids. After 2 hours of baseline biological samples of sweat, dermal interstitial fluid, and blood have been collected, we will provide a standardized meal as a liquid drink consisting of whey, maltodextrin and sunflower oil, flavored using vanilla sugar-free instant pudding. Biological sampling will continue to occur for the following 5 hours.

Titre officiel

Advancing Precision Nutrition: Wearable Technology for Noninvasive Insulin Monitoring

Conditions
Insulin Response
Autres identifiants de l'essai
  • 105-Sweat
Numéro NCT
Date de début (réel)
2025-09-11
Dernière mise à jour publiée
2025-11-28
Date de fin (estimée)
2026-12
Inscription (estimée)
32
Type d'essai
Interventionnel
PHASE
N/A
Statut
En recrutement
Objectif principal
Recherche fondamentale
Plan d'attribution
N/A
Modèle d'intervention
Groupe unique
Masquage
Aucun (ouvert)
Bras / Interventions
Groupe de participants/BrasIntervention/Traitement
ExpérimentalStandardized liquid meal drink
We will provide a standardized drink consisting of whey, maltodextrin and sunflower oil, flavored using vanilla sugar-free instant pudding.
Repas standardisé
We will use Whey powder (60g) as protein, Maltodextrin (Polycose; 170g) as carbohydrate, and Sunflower Oil (48g) as the fat source. The meal is mixed and flavored using vanilla sugar-free instant pudding.
Critère principal d'évaluation
Critères d'évaluationDescription de critèresPériode
Quantification of protein biomarkers
Time-varying plasma insulin concentrations and correlation between sweat and dermal interstitial fluid.
up to 9 hours, 1 day
Critères d'éligibilité

Âges éligibles
Adulte, Adulte âgé
Âge minimum
18 Years
Sexes éligibles
Tous
Accepte les volontaires en bonne santé
Oui
  • Age

    • 18-30 years old
    • 50-90 years old
  • BMI between 22 and 35 kg/m2

  • Ability to walk, sit down, and stand up (independently or with a walking assistance device)

  • Willingness to lay supine in bed for up to 9 hours

  • Willingness and ability to comply with the protocol

  • Known allergy to any of the components of the meal or agents used for the application of the devices

    • Sunflower oil
    • Maltodextrin
    • Whey protein
    • Pilocarpine solutions
  • Established diagnosis and active treatment of chronic disease: insulin-dependent diabetes, active malignancy, heart failure, kidney disease, liver disease, HIV/AIDS, asthma (moderate to severe), Hep (A, B, or C)

  • History of untreated metabolic disease including hepatic or renal disorder

  • Presence of acute illness or metabolically unstable chronic illness

  • Active dependence on alcohol or drugs

  • Use of a short course of oral corticosteroids within 4 weeks preceding study day

  • Current use of long-term oral corticosteroids

  • Presence of fever within the last 3 days

  • Planned elective surgery requiring 2 or more days of hospitalization during the entire study

  • (Possible) pregnancy (confirmed via urine pregnancy test for females 18-30 years)

  • Failure to give informed consent or Investigator's uncertainty about the willingness or ability of the subject

  • Any condition according to the PI or nurse that was found during the screening visit, that would interfere with the study or safety of the patient

Texas A&M University logoTexas A&M University
Partie responsable de l'essai
Marielle PKJ Engelen, PhD, Investigateur principal, Professor, Texas A&M University
Contact central de l'essai
Contact: Nicolaas Deutz, 979-458-1484, [email protected]
Contact: Laura Ruebush, 979-458-1484, [email protected]
1 Centres de l'essai dans 1 pays

Texas

Texas A&M University, College Station, Texas, 77843, United States
Nicolaas Deutz, Contact
En recrutement